NextBio

Help
Description: Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to 5-fluorouracil in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
Drug Type: Small Molecule; Approved; Investigational
Pharmacology: Capecitabine is a fluoropyrimidine carbamate with antineoplastic activity indicated for the treatment of patients with metastatic breast cancer. It is an orally administered systemic prodrug of 5'-deoxy-5-fluorouridine (5'-DFUR) which is converted to 5-fluorouracil.
Mechanism of Action: Capecitabine is a prodrug that is selectively tumour-activated to its cytotoxic moiety, fluorouracil, by thymidine phosphorylase. Fluorouracil is further metabolized to two active metabolites, 5-fluoro-2-deoxyuridine monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP), within normal and tumour cells. FdUMP inhibits DNA synthesis by reducing normal thymidine production, while FUTP inhibits RNA and protein synthesis by competing with uridine triphosphate.3 The active moiety of capecitabine, fluorouracil, is cell cycle phase-specific (Sphase). Both normal and tumor cells metabolize 5-FU to 5-fluoro-2-deoxyuridine monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP). These metabolites cause cell injury by two different mechanisms. First, FdUMP and the folate cofactor, N5-10-methylenetetrahydrofolate, bind to thymidylate synthase (TS) to form a covalently bound ternary complex. This binding inhibits the formation of thymidylate from 2'-deaxyuridylate. Thymidylate is the necessary precursor of thymidine triphosphate, which is essential for the synthesis of DNA, so that a deficiency of this compound can inhibit cell division. Second nuclear transcriptional enzymes can mistakenly incorporate FUTP in place of uridine triphosphate (UTP) during the synthesis of RNA. This metabolic error can interfere with RNA processing and protein synthesis.
Indication: For the treatment of patients with metastatic breast cancer resistant to both paclitaxel and an anthracycline-containing chemotherapy regimen.
Half Life: 0.75 hours
View Complete Description



Data Correlations | 2 studies

Help for Data Correlations View All
Genes category icon Genes
Score Help
TYMS 100 100
RP4-662A9.2 100 100
CD300LF 93 93
152856 93 93
154907 89 89
FOXR2 86 86
View Top Genes
Biogroups category icon Biogroups
Score Help
One Carbon Pool by Folate 100 100
Pyrimidine Metabolism 95 95
View Top Biogroups

Individual Studies

  • Drug target sets for approved compounds

    Homo sapiens Homo sapiens | Therapeutic   Therapeutic

    The DrugBank database is a unique bioinformatics and cheminformatics resource that combines detailed drug (i.e. chemical, pharmacological and pharmaceutical) data with comprehensive drug target (i.e. sequence, structure, and pathway) information.

    Authors: David S Wishart, Craig Knox, An Chi Guo et al.

    Organization: Department of Computing Science, Univers…
View All Individual Studies

Associated Researchers

Help for Associated Researchers

Thought leaders and organizations working on research involving Xeloda.

View All Author iconAuthors
  • Pasquale Comella
  • David Cameron
  • Luca Franco
  • Rossana Casaretti
  • Judith Ebert
View All Clinical trial sponsors icon Clinical Trials Sponsors
  • Hoffmann-La Roche
  • James A. Haley Veterans Administration Hospital
  • Rambam Health Care Campus
  • Samsung Medical Center
  • M.D. Anderson Cancer Center
View All Affiliations icon Organizations
  • National Tumor Institute
  • Dana-Farber Cancer Institute
  • Rutgers University
  • University of Zurich
  • Monash University

Clinical Trials | 750 trials

Help for Clinical Trials View All

Community

Help for Community
NextBio Users

  • No NextBio users were found for “Xeloda”.
    Complete your user profile with your interests, if you want others to find you within the NextBio community.

NextBio Groups

  • No NextBio groups were found for “Xeloda”.
    Be the first to start a group and share your interests with others within the NextBio community.

© 2010 NextBio